ViGenCell Inc.

South Korean bioventure funding remained weak in the third quarter, with venture capital investment in the sector falling further from the previous three months, although a handful of companies manage

Investment in cell and gene therapies skyrocketed during the first half of 2021 to $14.1bn, the highest six-month total on record and up 35% from the first half of 2020, which was a record-breaking ye

Immune cell therapy company ViGenCell Inc. has kept the biopharma investment fervor going in South Korea, raising KRW99.4bn ($85m) from an initial public offering on the Kosdaq market. The stock was